Speaking to ET on the sidelines of the inauguration, Takeda’s chief data and technology officer, Gabriele Ricci, said the company chose Bengaluru for its robust talent pool in data, digital, and technology, as well as its unique ecosystem of academia, startups, and tech partners.
The CTO said it views AI as a key enabler in drug discovery, clinical trials, manufacturing, and patient care. “We are living in amazing times with the intersection of science and technology. Emerging technologies like AI, generative AI, and robotics offer unique opportunities to create solutions that can impact healthcare systems worldwide,” Ricci said.
Ricci added that the Bengaluru facility will focus on developing products such as a plasma-derived therapies donor management system and a global platform for healthcare professional (HCP) data. “The Indian team will also develop scalable, multi-language tools and other digital products to enhance patient support and care experiences,” he said.
Over the next few years, Takeda plans to expand its focus on therapeutic areas such as inflammation, oncology, and rare conditions, with investments in plasma-derived therapies and vaccines, Ricci said during the ICC launch.
The company is currently undergoing clinical trials and regulatory approvals to launch its Dengue vaccine– Qdenga, in Indian markets by 2026. Takeda plans to leverage local manufacturing under the ‘Make in India’ initiative to deliver the vaccine.
Discover the stories of your interest
The pharma company has been improving its high-value late stage pipeline with plans to file eight regulatory filings between 2025-2029 and make revenue of $10 billion to $20 billion, as per Takeda’s official website.
